Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pramiconazole (R126638) 是一种可口服的抗真菌化合物。Pramiconazole 是治疗皮肤癣菌和皮肤酵母菌感染的候选化合物,可用于治疗脂溢性皮炎。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 3,820 | 现货 | ||
5 mg | ¥ 8,470 | 现货 | ||
10 mg | ¥ 11,300 | 现货 | ||
25 mg | ¥ 16,900 | 现货 | ||
50 mg | ¥ 22,800 | 现货 | ||
100 mg | ¥ 29,700 | 现货 |
产品描述 | Pramiconazole (R126638) is an orally available antifungal compound.Pramiconazole is a candidate for the treatment of dermatophytes and cutaneous yeast infections in seborrheic dermatitis. |
体内活性 | This study was performed in 2 groups of subjects suffering from seborrheic dermatitis. The first group (n = 17) remained untreated and was used as a control. Clinical, mycological, and metrological assessments were performed at inclusion and during the following 2 weeks. The second group of subjects (n = 10) received a single 200-mg oral dose of pramiconazole at inclusion. Clinical, mycological, and bio-metrological evaluations were performed before and during 1 month following the single antifungal intake. For both parts of the study, several parameters were assessed including yeast density, desquamation, erythema, itching, and sebum excretion. Results: In the control group, no significant changes were observed in any of the parameters during the observation period. The findings were markedly different in the pramiconazole-treated subjects. The yeast density was significantly improved on days 3, 7, and 28. Desquamation, erythema, itching, and the global clinical evaluation as assessed by the patients and investigators significantly improved on days 7 and 28. A trend in the decrease of scaliness was noted. No effect on sebum excretion was evidenced. In conclusion, a single 200-mg dose of pramiconazole exhibits in vivo efficacy in controlling some important clinical aspects of seborrheic dermatitis. Following a reduction in the number of yeasts on day 3, a decrease in the severity of clinical signs and symptoms occurred from day 7 onwards. Sebum excretion appeared uninvolved in the clearing process of seborrheic dermatitis. A single 200-mg dose of pramiconazole appears to abate seborrheic dermatitis. The density in Malassezia present on lesional skin is first decreased, followed by clearing of the clinical signs.[3] |
别名 | R-126638, R126638, R 126638, Azoline |
分子量 | 659.73 |
分子式 | C35H39F2N7O4 |
CAS No. | 219923-85-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 6.25 mg/mL (9.47 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.5158 mL | 7.5789 mL | 15.1577 mL | 37.8943 mL |
5 mM | 0.3032 mL | 1.5158 mL | 3.0315 mL | 7.5789 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Pramiconazole 219923-85-0 Microbiology/Virology Antifungal R-126638 R126638 R 126638 Azoline Inhibitor inhibitor inhibit